Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
BMC Immunol ; 14 Suppl 1: S11, 2013.
Article in English | MEDLINE | ID: mdl-23458421

ABSTRACT

The development of a new tuberculosis (TB) vaccine has become one of the main objectives of the scientific community. Protein antigens have been widely explored as subunit TB vaccines, however lipid antigens could be equally important to be used or included in such a vaccine. The aim of this study was to demonstrate the potential of a liposome formulation composed of an extract of lipids from Mycobacterium smegmatis (Ms) as a TB vaccine candidate. We evaluated the immunogenicity of this formulation as well as the cross reactive response against antigens from Mycobacterium tuberculosis (MTb) in BALB/c mice. We determined the anti-liposome IgG response in sera from TB patients and from healthy subjects who displayed a positive (PPD+) or negative (PPD-) tuberculin skin test. A significant increase in anti-liposome IgG (p<0.05) was detected in animals immunized with Bacille Calmette-Guérin (BCG) compared with all groups, and in the group immunized with liposomes from Ms (LMs) compared to animals immunized with either LMs adjuvanted with aluminium (LMs-A) or the negative control group (phosphate buffered saline, PBS) respectively. With respect to the cross reactive response against a cocktail of cell wall antigens (CWA) from MTb, significantly higher IgG levels were observed in animals immunized with BCG and LMs compared to negative controls and either, aluminium-adjuvanted liposomes (LMs-A) or montanide (LMs-M) (p<0.05). Furthermore, the anti-liposome IgG response was significantly superior in sera from pulmonary TB patients compared to PPD+ and PPD- healthy subjects (p<0.001) suggesting the expression of these antigens in vivo during active MTb infection. The results obtained provide some evidence for the potential use of liposomes containing total lipid extracts of Ms as a TB vaccine candidate.


Subject(s)
Liposomes/immunology , Mycobacterium smegmatis/immunology , Mycobacterium tuberculosis/immunology , Tuberculosis Vaccines/immunology , Animals , Cell Wall/immunology , Cross Reactions , Female , Immunity, Humoral , Immunoglobulin G/immunology , Liposomes/administration & dosage , Mice , Mice, Inbred BALB C , Mycobacterium bovis/immunology , Tuberculin Test , Tuberculosis/immunology , Tuberculosis/prevention & control , Vaccination
2.
Histochem Cell Biol ; 134(2): 137-44, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20607275

ABSTRACT

Agmatinase catalyzes the hydrolysis of agmatine into putrescine and urea, and agmatine (decarboxylated L: -arginine) plays several roles in mammalian tissues, including neurotransmitter/neuromodulatory actions in the brain. Injection of agmatine in animals produces anticonvulsant, antineurotoxic and antidepressant-like actions. Information regarding the enzymatic aspects of agmatine metabolism in mammals, especially related to its degradation, is relatively scarce. The explanation for this is the lack of enzymatically active preparations of mammalian agmatinase. Recently, we have cloned a protein from a cDNA rat brain library having agmatinase activity although its amino acid sequence greatly differs from all known agmatinases, we called agmatinase-like protein. In this work, we analyzed the expression of this enzyme in the rat brain by means of RT-PCR and immunohistochemical analysis using a polyclonal antibody generated against the recombinant agmatinase-like protein. The agmatinase-like protein was detected in the hypothalamus in glial cells and arcuate nucleus neurons, and in hippocampus astrocytes and neurons, but not in brain cortex. In general, detected localization of agmatinase-like protein coincides with that described for its substrate agmatine and our results help to explain several reported effects of agmatine in the brain. Concretely, a role in the regulation of intracellular concentrations of the neurotransmitter/neuromodulator agmatine is suggested for the brain agmatinase-like protein.


Subject(s)
Brain/enzymology , Ureohydrolases/analysis , Agmatine/metabolism , Animals , Brain Chemistry , Hypothalamus/enzymology , Neuroglia/enzymology , Rats , Recombinant Proteins/analysis , Tissue Distribution
3.
J Cell Mol Med ; 13(9B): 3973-84, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19602043

ABSTRACT

Breast cancers increase glucose uptake by increasing expression of the facilitative glucose transporters (GLUTs), mainly GLUT1. However, little is known about the relationship between GLUT1 expression and malignant potential in breast cancer. In this study, expression and subcellular localization of GLUT1 was analysed in vivo in breast cancer tissue specimens with differing malignant potential, based on the Scarff-Bloom-Richardson (SBRI, II, III) histological grading system, and in vitro in the breast cancer cell lines, MDA-MB-468 and MCF-7, and in MDA-MB-468 cells grown as xenografts in nude athymic BALB/c male mice. In situ hybridization analyses demonstrated similar levels of GLUT1 mRNA expression in tissue sections from breast cancers of all histological grades. However, GLUT1 protein was expressed at higher levels in grade SBRII cancer, compared with SBRI and SBRIII, and associated with the expression of the proliferation marker PCNA. Immunolocalization analyses in SBRII cancers demonstrated a preferential localization of GLUT1 to the portions of the cellular membrane that faced neighbouring cells and formed 'canaliculi-like structures', that we hypothesize could have a potential role as 'nutritional channels'. A similar pattern of GLUT1 localization was observed in confluent cultures of MDA-MB-468 and MCF-7, and in MDA-MB-468 cells grown as xenografts, but not in the normal breast epithelial cell line HMEC. However, no relationship between GLUT1 expression and malignant potential of human breast cancer was observed. Preferential subcellular localization of GLUT1 could represent a physiological adaptation of a subset of breast cancer cells that form infiltrative tumours with a nodular growth pattern and that therefore need a major diffusion of glucose from blood vessels.


Subject(s)
Breast Neoplasms/metabolism , Gene Expression Regulation, Neoplastic , Animals , Breast/pathology , Breast Neoplasms/pathology , Cell Line, Tumor , Cytological Techniques , Female , Glucose Transporter Type 1/metabolism , Humans , In Situ Hybridization , Male , Mammary Neoplasms, Experimental/pathology , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasm Transplantation
4.
J Neurochem ; 108(3): 563-77, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19054284

ABSTRACT

Ascorbic acid (AA) is best known for its role as an essential nutrient in humans and other species. As the brain does not synthesize AA, high levels are achieved in this organ by specific uptake mechanisms, which concentrate AA from the bloodstream to the CSF and from the CSF to the intracellular compartment. Two different isoforms of sodium-vitamin C co-transporters (SVCT1 and SVCT2) have been cloned. Both SVCT proteins mediate high affinity Na(+)-dependent L-AA transport and are necessary for the uptake of vitamin C in many tissues. In the adult brain the expression of SVCT2 was observed in the hippocampus and cortical neurons by in situ hybridization; however, there is no data regarding the expression and distribution of this transporter in the fetal brain. The expression of SVCT2 in embryonal mesencephalic neurons has been shown by RT-PCR suggesting an important role for vitamin C in dopaminergic neuronal differentiation. We analyze SVCT2 expression in human and rat developing brain by RT-PCR. Additionally, we study the normal localization of SVCT2 in rat fetal brain by immunohistochemistry and in situ hybridization demonstrating that SVCT2 is highly expressed in the ventricular and subventricular area of the rat brain. SVCT2 expression and function was also confirmed in neurons isolated from brain cortex and cerebellum. The kinetic parameters associated with the transport of AA in cultured neurons and neuroblastoma cell lines were also studied. We demonstrate two different affinity transport components for AA in these cells. Finally, we show the ability of different flavonoids to inhibit AA uptake in normal or immortalized neurons. Our data demonstrates that brain cortex and cerebellar stem cells, neurons and neuroblastoma cells express SVCT2. Dose-dependent inhibition analysis showed that quercetin inhibited AA transport in cortical neurons and Neuro2a cells.


Subject(s)
Brain Neoplasms/metabolism , Brain Stem/metabolism , Flavonoids/pharmacology , Neuroblastoma/metabolism , Neurons/metabolism , Organic Anion Transporters, Sodium-Dependent/antagonists & inhibitors , Organic Anion Transporters, Sodium-Dependent/biosynthesis , Sodium/physiology , Symporters/antagonists & inhibitors , Symporters/biosynthesis , Animals , Ascorbic Acid/metabolism , Blotting, Western , Brain Stem/cytology , Cell Line, Tumor , Cerebellum/cytology , Cerebellum/drug effects , Cerebellum/metabolism , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , DNA, Complementary/biosynthesis , DNA, Complementary/genetics , Female , Humans , Immunohistochemistry , In Situ Hybridization , Kinetics , Mice , Neurons/drug effects , Pregnancy , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction , Sodium-Coupled Vitamin C Transporters
5.
Kidney Int ; 74(10): 1278-86, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18614995

ABSTRACT

Vitamin C is reabsorbed from the renal lumen by one isoform of sodium-vitamin C co-transporters that mediate high affinity sodium-dependent L-ascorbic acid transport. Sodium-vitamin C cotransporter-1 mRNA has been detected in intestine and liver and the S3 segment of the renal proximal tubule. Here, we found that its distribution was broader and all three proximal tubule segments of mouse and human expressed the transporter but the S3 segment had the highest expression. Sodium-vitamin C co-transporter-1 expression was also found in the renal epithelial-derived LLC-PK1 cell line. Ascorbic acid transport in these cells was regulated by a single kinetic component that depended on the sodium concentration, pH and temperature. Reducing ascorbate concentration increased the apical expression of the transporter suggesting the presence of a feedback system for regulation of transporter abundance at the luminal membrane.


Subject(s)
Ascorbic Acid/metabolism , Sodium/metabolism , Symporters/metabolism , Absorption , Animals , Humans , Hydrogen-Ion Concentration , Intestines/chemistry , Kidney Tubules, Proximal/chemistry , Kinetics , Liver/chemistry , Mice , RNA, Messenger/analysis , Temperature
6.
Environ Mol Mutagen ; 45(1): 1-7, 2005.
Article in English | MEDLINE | ID: mdl-15605354

ABSTRACT

The VIII Region of Bio-Bio is a major fruit-growing area of Chile that makes intensive use of agricultural pesticides. The cytogenetic damage associated with exposure to mixtures of pesticides was evaluated by comparing peripheral blood lymphocyte micronucleus (MN) frequencies in a group of 64 female agricultural workers and 30 female controls. The exposed subjects worked during the spring and summer in thinning and pruning fruit trees and in harvesting and packing different fruits, such as raspberries, grapes, apples, and kiwis. They did not use any protective measures during their work activities. A significant increase in the frequency of binucleated cells with micronuclei (BNMN) was found in the exposed women as compared with the controls (36.94 +/- 14.47 vs. 9.93 +/- 6.17 BNMN/1000 BN cells; P < 0.001). The frequency of BNMN varied as a function of age in both the exposed and control groups, but no correlation was found between BNMN frequency and the duration of exposure. Also, smoking and other habits had no effect on MN frequency. Our study confirms that occupational exposure to pesticide mixtures results in cytogenetic damage.


Subject(s)
Chromosome Aberrations/chemically induced , Occupational Exposure , Pesticides/toxicity , Age Factors , Agrochemicals/toxicity , Case-Control Studies , Chile , Female , Humans , Micronucleus Tests , Time Factors
7.
J Endocrinol ; 182(3): 467-78, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15350188

ABSTRACT

Estrogen replacement therapy and other unopposed estrogen treatments increase the incidence of endometrial abnormalities, including cancer. However, this effect is counteracted by the co-administration of progesterone. In the endometrium, glucose transporter (GLUT) expression and glucose transport are known to fluctuate throughout the menstrual cycle. Here, we determined the effect of estrogen and progesterone on the expression of GLUT1-4 and on the transport of deoxyglucose in Ishikawa endometrial cancer cells. Cells were incubated with estrogen, progesterone or combined estrogen and progesterone for 24 h and the effect on the expression of GLUT1-4 and on deoxyglucose transport was determined. We show that GLUT1 expression is upregulated by estrogen and progesterone individually, but that combined estrogen and progesterone treatment reverses this increase. Hormonal treatments do not affect GLUT2, GLUT3 or GLUT4 expression. Transport studies demonstrate that estrogen increases deoxyglucose transport at Michaelis-Menten constants (Kms) corresponding to GLUT1/4, an effect which disappears when progesterone is added concomitantly. These data demonstrate that different hormonal treatments differentially regulate GLUT expression and glucose transport in this endometrial cancer cell line. This regulation mirrors the role played by estrogen and progesterone on the incidence of cancer in this tissue and suggests that GLUT1 may be utilized by endometrial cancer cells to fuel their demand for increased energy requirement.


Subject(s)
Endometrial Neoplasms/metabolism , Estrogens/pharmacology , Gene Expression Regulation , Monosaccharide Transport Proteins/metabolism , Progesterone/pharmacology , Biological Transport , Blotting, Western/methods , Cell Line, Tumor , Deoxyglucose/analysis , Deoxyglucose/metabolism , Female , Glucose Transporter Type 1 , Glucose Transporter Type 2 , Glucose Transporter Type 3 , Glucose Transporter Type 4 , Humans , Immunohistochemistry/methods , Monosaccharide Transport Proteins/analysis , Muscle Proteins/analysis , Muscle Proteins/metabolism , Nerve Tissue Proteins/analysis , Nerve Tissue Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction
8.
J Cell Physiol ; 205(1): 19-24, 2005 Oct.
Article in English | MEDLINE | ID: mdl-15965961

ABSTRACT

Several reports have indicated the absence of gluconeogenic enzymes in pancreatic islet cells. In contrast, here we demonstrate that liver fructose-1,6-bisphosphatase (FBPase) is highly expressed both in human and rat pancreas. Interestingly, pancreatic FBPase is active and functional, and is inhibited by AMP and fructose-2,6-bisphosphate (Fru-2,6-P2). These results suggest that FBPase may participate as a component of a metabolic sensing mechanism present in the pancreas. Immunolocalization analysis showed that FBPase is expressed both in human and rat Langerhans islets, specifically in beta cells. In humans, FBPase was also located in the canaliculus and acinar cells. These results indicate that FBPase coupled with phosphofructokinase (PFK) plays a crucial role in the metabolism of pancreatic islet cells. The demonstration of gluconeogenic recycling of trioses as a new metabolic signaling pathway may contribute to our understanding of the differences between the insulin secretagogues trioses, fructose, and glucose in pancreas.


Subject(s)
Fructose-Bisphosphatase/metabolism , Gene Expression Regulation, Enzymologic , Islets of Langerhans/enzymology , Liver/enzymology , Animals , Fructose-Bisphosphatase/genetics , Humans , Kidney/enzymology , Male , Organ Specificity , Rats
9.
Neurochem Res ; 29(1): 127-34, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14992271

ABSTRACT

Ependymal cells have been reported to express the facilitative glucose carriers GLUT1, GLUT2, and GLUT4, as well as glucokinase. They are therefore speculated to be part of the cerebral glucose sensing system and may also respond to insulin with alterations in their glucose uptake rate. A cell culture model was employed to study the functional status of ependymal insulin-regulated glucose uptake in vitro. Insulin increased the uptake of the model substrate 2-deoxyglucose (2-DG) dependent on the insulin concentration. This was due to a near doubling of the maximal 2-DG uptake rate. Insulin-like growth factor (IGF-1) was at least 10 times more potent than insulin in stimulating the rate of ependymal 2-DG uptake, suggesting that IGF-1, rather than insulin, is the physiological agonist regulating glucose transport in ependymal cells. The predominant glucose transporter in ependymal cell cultures was found to be GLUT1, which is apparently regulated by IGF-1 in ependymal cells.


Subject(s)
Deoxyglucose/metabolism , Ependyma/metabolism , Insulin-Like Growth Factor I/physiology , Insulin/physiology , Base Sequence , DNA Primers , Ependyma/cytology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL